Eletriptan (Relpax)
Small molecule
Evidence outlook
Approved: Migraine
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Latest reported trial: NCT01978496 · Phase 3 · met primary endpoint · grade pending
Also approved (1)
- Acute treatment of migraine (Relpax tablets 20 mg; approval number 21400AMZ00463)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01978496 NCT01978496 · Migraine Registry: NCT01978496 | 3 | Headache responder rate at two hours after the first dose for the first attack. (2 hours) 1997-12 | 2-hour headache response was 47%, 62% and 59% on eletriptan 20, 40 and 80 mg vs 22% on placebo (P <.0001). | not yet graded | link ↗ |
View 2 more trials
NCT01986088 NCT01986088 · Migraine Registry: NCT01986088 | 3 | Headache response at 1 hour after treatment of the first attack. 1998-01 | 1-hour headache response: 12% placebo, 24% and 27% sumatriptan 50/100 mg, 30% and 37% eletriptan 40/80 mg. | not yet graded | link ↗ |
NCT01859481 NCT01859481 · Migraine Registry: NCT01859481 | 3 | Consistency of headache response (3 responses out of 3 active treated attacks) . Headache response was defined as migraine headache pain of moderate or severe intensity pre dose becoming basent or mild within 2 hours post dose. (24 weeks) 2002-03 | Within-patient consistency of 2-hour headache response: 77% (40 mg) and 73% (80 mg) for at least 2 of 3 attacks; 46% and 47% for 3 of 3. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Competitive landscape
Other 5-HT1B/1D receptor drugs
Frovatriptan (Frova), Meloxicam/Rizatriptan (Symbravo), Naratriptan (Amerge), Rizatriptan (Maxalt), Rizatriptan (RizaFilm) and 10 more. Compare all 16 5-HT1B/1D receptor drugs
This mechanism is crowded: 17 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Migraine: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Eletriptan (Relpax): this drug | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aspirin / Acetaminophen / Caffeine (Excedrin Migraine) | Approved | — | Nonsteroidal Anti-inflammatory Drug, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Atogepant (Qulipta) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT03777059: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) NCT02848326: Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33) | |
| Celecoxib (Elyxyb) | Approved | Small molecule | COX-2 | Partial signal | No reviewed efficacy summary in this indication | |
| Diclofenac Potassium (Cambia) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine (Atzumi) | Approved | Small molecule | 5-HT1D receptor | Partial signal | NCT04940390: Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. missed NCT03901482: Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. missed | |
| Dihydroergotamine Mesylate (Brekiya) | Approved | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate (D.H.E. 45) | ApprovedUS marketing discontinued | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate (Migranal) | Approved | Small molecule | 5-HT1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote ER) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Eptinezumab (Vyepti) | Approved | Monoclonal antibody | CGRP ligand | Reliable signal | NCT02974153: Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9) NCT02559895: Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7) | |
| Erenumab (Aimovig) | Approved | Monoclonal antibody | CGRP receptor | Reliable signal | NCT03867201: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT02456740: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) | |
| Ergotamine / Caffeine (Cafergot) | ApprovedUS marketing discontinued | Small molecule | Alpha-adrenergic receptor, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Fremanezumab (Ajovy) | Approved | Monoclonal antibody | CGRP ligand | Partial signal | NCT04458857: Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results). NCT02621931: Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results). | |
| Frovatriptan (Frova) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Galcanezumab (Emgality) | Approved | Monoclonal antibody | CGRP ligand | Reliable signal | NCT03963232: Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001. NCT03559257: Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001. | |
| Ibuprofen (Advil Migraine) | Approved | Small molecule | Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Meloxicam / Rizatriptan (Symbravo) | Approved | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | Reliable signal | Featured results are safety only in this race | |
| Naratriptan (Amerge) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| onabotulinumtoxinA (Botox) | Approved | Biologic (subtype unspecified) | Acetylcholine Release Inhibitor, acetylcholine release | not yet graded | No reviewed efficacy summary in this indication | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Rimegepant (Nurtec ODT) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT05810038: Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05399485: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) | |
| Rizatriptan (Maxalt) | Approved | Small molecule | 5-HT1B/1D receptor | Partial signal | Featured results are non-efficacy only in this race | |
| Rizatriptan (RizaFilm) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan (Onzetra Xsail) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan (Tosymra) | Approved | Small molecule | 5-HT1B/1D receptor | Weak signal | Featured results are safety only in this race | |
| Sumatriptan Succinate (Sumavel DosePro) | ApprovedUS marketing discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate (Zembrace SymTouch) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Injection (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Nasal Spray (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate Tablets (Imitrex) | Approved | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan / Naproxen Sodium (Treximet) | Approved | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | Weak signal | No reviewed efficacy summary in this indication | |
| Topiramate (Eprontia) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Qudexy XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax Sprinkle) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Topiramate (Topamax) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | Partial signal | NCT00236509: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001). | |
| Topiramate (Trokendi XR) | Approved | Small molecule | Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase | not yet graded | No reviewed efficacy summary in this indication | |
| Ubrogepant (Ubrelvy) | Approved | Small molecule | CGRP receptor | Reliable signal | NCT04492020: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants | |
| Zavegepant (Zavzpret) | Approved | Small molecule | CGRP receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Zolmitriptan (Zomig Nasal Spray) | Approved | Small molecule | 5-HT1B/1D receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Almotriptan (Axert) | US approval withdrawn | Small molecule | 5-HT1B/1D receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Elismetrep | Phase 3 | — | TRPM8 | not yet graded | No reviewed efficacy summary in this indication | |
| IncobotulinumtoxinA (Xeomin) | Phase 3 | Protein / enzyme therapeutic | acetylcholine release | not yet graded | No reviewed efficacy summary in this indication | |
| Rizatriptan / Naproxen | Phase 3 | Small molecule | 5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drug | not yet graded | No reviewed efficacy summary in this indication | |
| Naltrexone / Acetaminophen (ALLOD-2) | Phase 2/3 | — | Opioid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BHV-2100 | Phase 2 | — | TRPM3 | not yet graded | No reviewed efficacy summary in this indication | |
| EVO756 | Phase 2 | Small molecule | MRGPRX2 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-2002 | —(overall) | Undisclosed | PAR-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv) | —(overall) | — | 5-HT1D receptor, Adenosine receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Dipyrone / Isometheptene Mucate / Caffeine (Neosaldina) | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lasmiditan (Reyvow) | Discontinued | Small molecule | 5-HT1F receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Propranolol (Inderal) | Discontinued | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| Sumatriptan Succinate (Zecuity) | Discontinued | Small molecule | 5-HT1B/1D receptor | Partial signal | Featured results are non-efficacy and safety only in this race | |
| Sumatriptan Succinate Auto-Injector (Alsuma) | Discontinued | Small molecule | 5-HT1B/1D receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Zolmitriptan (Zomig) | Discontinued | Small molecule | 5-HT1B/1D receptors | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Eletriptan (Relpax) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.